Source:http://linkedlifedata.com/resource/pubmed/id/10955237
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0008848,
umls-concept:C0012655,
umls-concept:C0013227,
umls-concept:C0080194,
umls-concept:C0205164,
umls-concept:C0205409,
umls-concept:C0282386,
umls-concept:C0427965,
umls-concept:C0442027,
umls-concept:C0733511,
umls-concept:C1136254,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1533693,
umls-concept:C2607850
|
pubmed:issue |
6
|
pubmed:dateCreated |
2000-10-17
|
pubmed:abstractText |
To evaluate the resistance for major oral antimicrobial agents, mainly new quinolones, we carried out a drug susceptibility surveillance of 3,050 strains of 11 microbial species clinically isolated at 8 institutions such as general hospitals and examination centers in Hiroshima city. 10 antimicrobial agents were used: 3 new quinolone drugs, 5 beta-lactam drugs, minocycline and clarithromycin. Among Gram-positive bacteria, methicillin resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis showed low susceptibility to the new quinolone drugs, while methicillin susceptible Staphylococcus aureus (MSSA) and Streptococcus pneumoniae were highly sensitive to these drugs. Among Gram-negative bacteria, Pseudomonas aeruginosa showed high resistance for the new quinolone drugs, but enteric bacteria and Haemophilus influenzae did not show marked resistance, maintaining almost good sensitivity to these drugs. To reduce the appearance of resistant bacteria, appropriate antimicrobial agents should be selected. Drug susceptibility surveillance in the community will be also important in the future.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/4-Quinolones,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Infective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Clarithromycin,
http://linkedlifedata.com/resource/pubmed/chemical/Lactams,
http://linkedlifedata.com/resource/pubmed/chemical/Minocycline
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0368-2781
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
53
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
409-21
|
pubmed:dateRevised |
2009-11-11
|
pubmed:meshHeading |
pubmed-meshheading:10955237-4-Quinolones,
pubmed-meshheading:10955237-Administration, Oral,
pubmed-meshheading:10955237-Anti-Infective Agents,
pubmed-meshheading:10955237-Clarithromycin,
pubmed-meshheading:10955237-Drug Resistance, Microbial,
pubmed-meshheading:10955237-Gram-Negative Bacteria,
pubmed-meshheading:10955237-Gram-Positive Bacteria,
pubmed-meshheading:10955237-Haemophilus influenzae,
pubmed-meshheading:10955237-Humans,
pubmed-meshheading:10955237-Lactams,
pubmed-meshheading:10955237-Minocycline,
pubmed-meshheading:10955237-Pseudomonas aeruginosa
|
pubmed:year |
2000
|
pubmed:articleTitle |
[Results of antimicrobial susceptibilities of strains clinically isolated at 8 institutions in Hiroshima City to major oral antimicrobial drugs, mainly new quinolone drugs. Hiroshima Levofloxacin Susceptibility Surveillance Group].
|
pubmed:affiliation |
Department of Pathology and Clinical Laboratory Medicine, Hiroshima Prefectural Hospital.
|
pubmed:publicationType |
Journal Article,
English Abstract
|